title: Colonic delivery of celecoxib is a potential pharmaceutical strategy for repositioning the selective COX-2 inhibitor as an anti-colitic agent.
abstract: Celecoxib is a selective cyclooxygenase-2 inhibitor applied to the treatment of arthritis. Repositioning the anti-inflammatory drug as an anti-inflammatory bowel disease drug has obstacles such as controversial anti-colitic efficacy and potential side effects. We examined whether colonic delivery of celecoxib could circumvent the therapeutic limitations. N-succinylglutam-1-yl celecoxib (SG1C), a colon-specific prodrug of celecoxib), was administered orally to rats with colitis and the anti-inflammatory activity and pharmacologic mechanisms were investigated. SG1C alleviated the colonic injury and lowered myeloperoxidase activity in the inflamed colonic tissues much more effectively than conventional celecoxib. While suppressing expression of pro-inflammatory nuclear factor kappaB gene products including cyclooxygenase-2, SG1C elevated an anti-inflammatory nuclear factor-erythroid 2 p45 (NF-E2)-related factor 2 (Nrf2) and its target gene product heme oxygenase (HO)-1 in the inflamed colon. In contrast, no significant molecular effects were observed with conventional celecoxib. Unlike conventional celecoxib, SG1C did not lower the serum level of 6-keto-PGF1α, an inverse indicator of cardiovascular adverse effects. Collectively, colonic delivery of celecoxib, likely improving therapeutic and toxicological properties of celecoxib, may be a feasible pharmaceutical strategy to therapeutically switch celecoxib to an anti-colitic drug.
authors: College of Pharmacy, Pusan National University, Busan, 609-735, South Korea. b04420@pusan.ac.kr.
authors: Wooseong
authors: W
authors: Kim
authors: College of Pharmacy, Pusan National University, Busan, 609-735, South Korea. yonghyunlee@kaist.ac.kr.|Bio-Nanomedicine Laboratory, Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, 305-701, South Korea. yonghyunlee@kaist.ac.kr.
authors: Yonghyun
authors: Y
authors: Lee
authors: College of Pharmacy, Pusan National University, Busan, 609-735, South Korea. finesiecle@gmail.com.
authors: Seongkeun
authors: S
authors: Jeong
authors: College of Pharmacy, Pusan National University, Busan, 609-735, South Korea. nj7777@naver.com.
authors: Joon
authors: J
authors: Nam
authors: College of Pharmacy, Pusan National University, Busan, 609-735, South Korea. lsy90003@naver.com.
authors: Sunyoung
authors: S
authors: Lee
authors: College of Pharmacy, Pusan National University, Busan, 609-735, South Korea. jungy@pusan.ac.kr.
authors: Yunjin
authors: Y
authors: Jung
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology; D003092:Colitis / Q000188:drug therapy* / Q000473:pathology; D003106:Colon / Q000378:metabolism* / Q000473:pathology; D052246:Cyclooxygenase 2 Inhibitors / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D004195:Disease Models, Animal; D058492:Drug Repositioning; D005971:Glutamates / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D045325:HCT116 Cells; D006801:Humans; D008297:Male; D016328:NF-kappa B / Q000378:metabolism; D011355:Prodrugs; D051381:Rats; D017207:Rats, Sprague-Dawley; D013449:Sulfonamides / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology
chemical_list: D000893:Anti-Inflammatory Agents; D052246:Cyclooxygenase 2 Inhibitors; D005971:Glutamates; C000609190:N-succinylglutam-1-yl celecoxib; D016328:NF-kappa B; D011355:Prodrugs; D013449:Sulfonamides
keywords: Cardiovascular toxicity; Celecoxib; Colon-specific prodrug; Drug delivery; Drug repositioning; Inflammatory bowel disease